GSK-588045
GSK-588045 is a serotonin 5-HT1A, 5-HT1B, and 5-HT1D receptor antagonist which was under development for the treatment of depressive and anxiety disorders but was never marketed. It is also a serotonin reuptake inhibitor, albeit much less potently than its serotonin 5-HT1 receptor antagonism. The drug increases brain serotonin levels in animals. It was being developed by GlaxoSmithKline. GSK-588045 reached phase 1 clinical trials prior to the discontinuation of its development.